Optimist Screening is currently undergoing clinical studies in the United States and the Dominican Republic. Our objective is to provide a true understanding on how critical the loss of smell as an early indicator of COVID-19, while determining other key parameters on the diagnosis of the virus at the same time. Patients are tested for anosmia–their ability to smell–whether they are asymptomatic and in early or late stages of the virus, at any severity of symptoms. Temperature and questionnaires are first performed and in some cases, bloodwork, MRI, and other tests are being related to the smell evaluation. We believe our positive preliminary data will create a need for Optimist Screening in flattening the curve and help reduce the chance of spreading the virus unknowingly to others.